WO2016187571A3 - Her2 immunotoxins and methods of using the same - Google Patents

Her2 immunotoxins and methods of using the same Download PDF

Info

Publication number
WO2016187571A3
WO2016187571A3 PCT/US2016/033594 US2016033594W WO2016187571A3 WO 2016187571 A3 WO2016187571 A3 WO 2016187571A3 US 2016033594 W US2016033594 W US 2016033594W WO 2016187571 A3 WO2016187571 A3 WO 2016187571A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
prevention
treatment
her2
Prior art date
Application number
PCT/US2016/033594
Other languages
French (fr)
Other versions
WO2016187571A2 (en
Inventor
Rachelle L. DILLON
Shilpa CHOONIEDASS
Jeannick Cizeau
Arjune Premsukh
Glen Macdonald
Original Assignee
Viventia Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Bio Inc. filed Critical Viventia Bio Inc.
Publication of WO2016187571A2 publication Critical patent/WO2016187571A2/en
Publication of WO2016187571A3 publication Critical patent/WO2016187571A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

The present invention relates to methods for preventing or treating cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell and; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of cancer using a recombinant immunotoxin comprising an anti-HER2/neu antibody or antibody fragment that is fused to a deimmunized bouganin toxin. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
PCT/US2016/033594 2015-05-20 2016-05-20 Her2 immunotoxins and methods of using the same WO2016187571A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562164444P 2015-05-20 2015-05-20
US62/164,444 2015-05-20
US201662278905P 2016-01-14 2016-01-14
US62/278,905 2016-01-14

Publications (2)

Publication Number Publication Date
WO2016187571A2 WO2016187571A2 (en) 2016-11-24
WO2016187571A3 true WO2016187571A3 (en) 2016-12-29

Family

ID=57320947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/033594 WO2016187571A2 (en) 2015-05-20 2016-05-20 Her2 immunotoxins and methods of using the same

Country Status (1)

Country Link
WO (1) WO2016187571A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021792A1 (en) * 2001-06-08 2003-01-30 Roben Paul W. Tissue-specific endothelial membrane proteins
US20050238642A1 (en) * 2004-03-19 2005-10-27 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
US20100322919A1 (en) * 2007-11-27 2010-12-23 Chahal Francina C Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof
US20120164068A1 (en) * 2009-07-03 2012-06-28 Peter John Hudson Immuno-conjugates and methods for producing them
US20130217865A1 (en) * 2004-06-10 2013-08-22 Viventia Biotechnologies Inc. Tumor Specific Antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021792A1 (en) * 2001-06-08 2003-01-30 Roben Paul W. Tissue-specific endothelial membrane proteins
US20050238642A1 (en) * 2004-03-19 2005-10-27 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
US20130217865A1 (en) * 2004-06-10 2013-08-22 Viventia Biotechnologies Inc. Tumor Specific Antibody
US20100322919A1 (en) * 2007-11-27 2010-12-23 Chahal Francina C Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof
US20120164068A1 (en) * 2009-07-03 2012-06-28 Peter John Hudson Immuno-conjugates and methods for producing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProtKB [o] 7 January 2015 (2015-01-07), "Full=rRNA N-glycosidase {ECO:0000256[RuleBase: RU 004915", Database accession no. Q8W4U4 *

Also Published As

Publication number Publication date
WO2016187571A2 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
CY1124791T1 (en) CD73-SPECIFIC BINDING MOLECULES AND USES THEREOF
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12019500270A1 (en) Combination therapy for cancer
MX2020008977A (en) Subcutaneous her2 antibody formulations.
JP2017506217A5 (en)
PH12017502270A1 (en) Combination therapy for the treatment of cancer
MA39070A1 (en) Anti-cd38 antibodies specific for the treatment of human cancers
RU2016146993A (en) Combination of anti-CCR4 antibody and 4-1BB agonist for cancer treatment
RU2014138038A (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER PREVENTION
RU2014138040A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
ZA201907225B (en) Treatment of her2 positive cancers
MX2019013753A (en) Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations.
MX2018014863A (en) Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein.
MX2020012755A (en) Anti-cd37 immunoconjugate dosing regimens.
MX2022002524A (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
MX2022001841A (en) Antibodies against ilt2 and use thereof.
MX2019011717A (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers.
FR3096259B1 (en) Antibody-drug conjugates and their use in therapy
MX2020010408A (en) Antibody-drug conjugates and their uses for the treatment of cancer.
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
Saini et al. Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment
WO2020176748A8 (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16797404

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16797404

Country of ref document: EP

Kind code of ref document: A2